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Abstract: Sudden cardiac death (SCD) is a serious public health problem; the annual
 incidence of out-of-hospital cardiac 
arrest in North
 America
 is approximately 166,200. Identifying patients at risk is a difficult proposition. At the present 
time, left ventricular ejection fraction (LVEF) remains the single most important marker for risk stratification. According 
to current guidelines, most patients with LVEF <35% could benefit from prophylactic ICD implantation, particularly in 
the setting of symptomatic heart failure. Current risk stratification strategies fail to identify patients at risk of SCD in 
larger population groups encompassing a greater number of potential SCD victims. However, the best approach to 
identifying patients and the value of various risk stratification tools is not entirely clear. The goal of this review is to 
discuss the problem of SCD and the value of the different risk stratification markers and their potential clinical use either 
alone or in combination with other risk stratification markers.  
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INTRODUCTION 
  Sudden cardiac death (SCD) is a serious public health 
problem, yet identifying patients at risk is a difficult 
proposition. Implantable cardioverter defibrillators (ICDs) 
have been shown to be beneficial in improving survival in 
patients at risk for SCD. However, the best approach to 
identifying patients and the value of various risk 
stratification tools is not entirely clear. The goal of this 
review is to discuss the problem of SCD in the context of 
methods to identify patients at risk, their relative value, and 
the concepts of relative and absolute risk reduction and 
number needed to treat as they help to frame the discussion 
of risk stratification and utilization of ICD therapy.  
STATEMENT OF THE PROBLEM: POPULATIONS 
AT RISK, RISK REDUCTION, AND NUMBER 
NEEDED TO TREAT 
  SCD is generally defined as a natural unexpected death 
due to cardiac causes occurring within one hour of the onset 
of acute symptoms [1]. Although difficult to measure, the 
annual
  incidence of out-of-hospital cardiac arrest in North
 
America
  is approximately 0.55 per 1000 population; this 
implies that approximately 166,200 out-of-hospital
  cardiac 
arrests occur annually [2].  
  Primary prevention trials of ICD therapy have established 
depressed left ventricular ejection fraction (LVEF) as the 
single most important risk stratification tool to identify 
individuals with a high risk of SCD [3-5]. In these trials, 
ICD therapy has provided an additional one-third 
incremental protection against all-cause mortality and SCD 
to the benefit obtained with optimal heart failure therapy 
alone [6] (Fig. 1).  
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  Despite the proven benefit of ICD therapy, risk 
stratification strategies based predominantly on severely 
depressed LVEF may not identify up to two-thirds of SCD 
victims who could potentially benefit from prophylactic 
ICDs and/or other therapeutic interventions [7-10]. This 
statistic is a natural consequence of the fact that the majority 
of potential SCD victims come from larger populations 
groups, such as those with coronary risk factors or the 
general population who either have preserved LVEFs or 
unrecognized LV dysfunction [11]. The implementation of 
prophylactic ICD therapy and/or other therapeutic 
intervention in these larger population groups is, at least 
partially, limited by their cost, risk-benefit ratio (number 
need to treat), impact on quality of life, the lack of reliable 
risk stratification tools in larger population groups, and lack 
of scientific evidence that ICD therapy improves survival in 
these lower risk populations.  
  Risk stratification strategies to identified potential SCD 
victims have been extensively studied in the last three 
decades. Three distinct types of SCD risk stratifiers can be 
identified: 
1.    Markers of abnormal substrate or structural heart 
disease: LVEF, non-sustained ventricular tachycardia 
(NSVT), frequent ventricular ectopy, QRS duration; 
2.    Markers of abnormal repolarization or electrical 
instability: electrophysiologic studies (EPS), T wave 
alternans (TWA), signal averaged ECG (SAECG), 
QT dispersion; 
3.   Markers of abnormal autonomic balance: heart rate 
variability (HRV) and baroreceptor sensitivity (BRS).  
  At present, it is unclear if these risk markers identify the 
same patient populations or provide complementary risk 
stratification information. The widespread utilization of each 
of these risk markers in clinical practice depends on their 
power as predictors of major cardiovascular events in 
specific patient populations.  Risk Stratification for Sudden Cardiac Death  Current Cardiology Reviews, 2009, Vol. 5, No. 1  57 
  Incorporation of a risk marker into clinical practice will 
depend on its power to predict adverse clinical outcomes if 
positive (positive predictive value, PPV) and/or their power 
to predict lack of adverse outcomes if negative (negative 
predictive value, NPV). Utilization of these markers also 
depends on the impact of their risk stratification power. For 
example, in the MADIT II trial, using LVEF <30% as a 
single risk stratifying tool, prophylactic ICD therapy reduced 
mortality from 19.8% in the conventional-therapy
 group to 
14.2% in the defibrillator group during an average follow-up
 
of 20 months. The relative risk reduction (RRR) of mortality 
was 31% and the absolute risk reduction (ARR) of mortality 
was 5.6%. That is, 18 defibrillators would need to be 
implanted to save a life (number needed to be treated, NNT) 
in MADIT II like patients [12,13]. The bottom line is that 
RRR and ARR are different ways of conveying the same 
information, yet they may be perceived very differently by 
patients and even by some health care providers.  
  The practice of medicine is largely based on application 
of a therapy or intervention in many individuals to prevent or 
avoid an adverse outcome in some. For example, data from 
16 individual trials of subjects treated with HMG-CoA 
reductase inhibitors (statin drugs) demonstrated a 28% RRR 
in cardiovascular mortality, but only a 1.7% decrease in 
ARR of cardiovascular mortality, during an average follow-
up of 3.3 years. In the GISSI trial, thrombolytic therapy was 
associated with a RRR in mortality of 18%, but the ARR in 
mortality was 2.3% [11,14,15]. Yet, both these therapies are 
well accepted in the care of patients with cardiovascular 
disease with lesser effects on mortality than most of the ICD 
trials.  
MARKERS OF ABNORMAL SUBSTRATE OR 
STRUCTURAL HEART DISEASE 
Depressed Left Ventricular Ejection Fraction 
  Primary prevention ICD trials had established depressed 
LVEF as the single most important risk stratification tool to 
identify individuals with a high risk of SCD. Data from 
seven primary prevention ICD trials have shown an average 
28% RRR and 3% ARR of death in ICD-treated patients as 
compared to medical therapy [3-5]. However, this benefit is 
most apparent in patients with the lowest LVEFs. A 
mortality analysis from the primary prevention ICD trials 
showed a RRR of death of 29% in patients with LVEF  
30%, but no significant mortality benefit for those with an 
LVEF >30% [4]. Similarly, in the AVID trial, patients with 
LVEF <35% had a significant survival benefit, whereas in 
patients with an LVEF 35, there was no difference in 
survival between ICD-treated patients and the medical 
therapy group.  
  Nonetheless, LVEF alone will not adequately identify 
populations at risk of SCD. In the Maastricht circulatory 
arrest registry, 56.5% of the SCD victims had an LVEF 
>30% and 20% had a LVEF >50%. Moreover, the interval 
between the last myocardial infarction (MI) and SCD was >2 
years in 66% of the victims (mean 6.5 years), and the 
interval between the first presentation with heart failure and 
SCD was 4.3±6.3 years, bringing into question the concept 
that cardiac events are time-dependent risk factors for SCD 
[8-11].  
  Similarly, in the Oregon Sudden Unexpected Death 
Study, the LVEF was severely (<35%) reduced in 36 patients 
(30%), mildly to moderately (36-54% LVEF) reduced in 27 
patients (22%), and normal in 58 patients (48%). Those with 
normal LVEF were younger and had a lower prevalence of 
established coronary artery disease [9].  
    The mean LVEF in the ICD trials for secondary 
prevention of SCD was 32% (AVID), 34% (CIDS) and 45% 
(CASH). Consequently, most patients in these trials had an 
LVEF >30% [16-18]. In these trials, an average of 35% RRR 
and 7.5% ARR of death in ICD-treated patients as compared 
to medical therapy was observed, over a follow-up period of 
11 to 36 months [3-5].  
  The prognostic value of a depressed LVEF appears to be 
influenced by other factors. Analysis of data from 674 
patients enrolled in the MUSTT study who did not receive 
 
Fig. (1). Results from clinical trials showing incremental decreases in mortality when added onto previous therapy. (Reprinted with 
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antiarrhythmic or ICD therapy revealed that other variables, 
such as: functional class, history of heart failure, NSVT, age, 
left ventricular conduction abnormalities, inducible sustained 
ventricular tachycardia, and atrial fibrillation influence 
arrhythmic death and total mortality risk. Patients with an EF 
30% but no other risk factors had a low predicted mortality 
risk. Patients with EF >30% and other risk factors may have 
a higher mortality and a higher risk of sudden death than 
some patients with EFs 30%. Thus, the risk of SCD in 
patients with coronary artery disease depends on multiple 
variables in addition to EF [19].  
Non-sustained Ventricular Tachycardia and Ventricular 
Ectopy 
  The frequency and complexity of ventricular arrhythmias 
increases as the LVEF deteriorates. However, there is 
dissociation between the frequency of ventricular arrhy-
thmias and the prevalence of SCD among patients with heart 
failure. Thus, a higher proportion of patients with New York 
Heart Association functional class I-II die suddenly (50-
60%) compared to patients with functional class III-IV 
(<30%), suggesting that NSVT and frequent ventricular 
ectopy are markers of abnormal substrate or structural heart 
disease rather than arrhythmic markers per se [20, 21]. This 
discordance between the prevalence of ventricular 
arrhythmias and outcomes was also corroborated in the 
CAST trial, which reported a significant increment in 
arrhythmic and non-arrhythmic cardiac death among post-MI 
patients treated with encainide and flecainide compared to 
placebo, despite suppression of ventricular ectopy with these 
drugs [22].  
  In a single center, prospective study of 700 post MI 
patients on adequate beta blocker therapy (>95% 
compliance) Huikuri et al. reported that SCD was weakly 
predicted by reduced EF (<0.40; p < 0.05), NSVT (p < 0.05), 
and an abnormal SAECG (p < 0.05), but not by autonomic 
markers (HVR, BRS) or standard ECG variables (QT 
dispersion, QT duration). The PPV of low EF, NSVT, and 
abnormal SAECG in predicting SCD (8%, 12%, and 13%, 
respectively) was lower than for non-sudden cardiac death 
(15%, 15%, and 18%, respectively) [23]. These observations 
indicate that low EF and NSVT are markers of increased 
cardiac mortality (arrhythmic and non-arrhythmic), but not 
good indicators of the specific mode of death.  
  The role of NSVT as a risk stratification tool was 
evaluated in three of the major primary prevention ICD trials 
(MUSTT, MADIT, DEFINITE). In two of these trials 
(MADIT, MUSTT), NSVT combined with depressed LVEF 
and inducible VT at EPS identified patients that benefited 
from a prophylactic ICD. DEFINITE was a primary 
prevention trial in patients with dilated, non-ischemic 
cardiomyopathy. Although a history of NSVT was necessary 
for enrollment in the study, EPS have not been shown to be 
helpful in such patients and were not included in the study 
procedures. Altogether, these trials showed a RRR of the 
primary endpoint (arrhythmic death or cardiac arrest, 
MUSTT) or mortality (MADIT, DEFINITE) of 76%, 56% 
and 35%, respectively with ICD therapy [5].  
  The role of NSVT and frequent ventricular ectopy as risk 
stratifying tools in patients with LVEF >40% is not clear at 
the present time.  
QRS Duration 
  A meta-analysis of primary prevention ICD trials showed 
that patients with QRS durations 120ms had a greater 
survival benefit than patients with QRS <120ms (RRR in 
mortality of 30% vs. 18%). However, the mortality benefit 
was significant in both groups [4].  
  In a prospective clinical trial, Chow et al. reported the 
prognostic value of TWA and QRS duration in 768 patients 
with ischemic cardiomyopathy (LVEF 35%) and no history 
of ventricular arrhythmias. During a mean follow-up of 
18+10 months, 99 patients died. After multivariable 
adjustment, a non-negative (positive or indeterminate) TWA 
test result was associated with a significantly higher risk for 
all-cause mortality in patients without ICDs and for all-cause 
mortality and appropriate ICD shocks in patients with an 
ICD. A QRS >120 ms was not associated with mortality 
outcomes, regardless of whether a QRS duration >120, >140, 
or >160 ms was used [24].  
 Similarly,  Bloomfield  et al. reported the prognostic value 
of TWA and QRS duration in 177 MADIT II-like patients. 
During an average follow-up of 20+6 months, 20 patients 
died. The mortality rate was substantially lower among 
patients with a normal TWA (<9%) than the mortality rate in 
patients with a narrow QRS (<18.5%) [25].  
  These data suggest that QRS duration does not provide 
significant additional prognostic value over and above that of 
LVEF, NSVT and TWA. It is not clear if QRS duration 
could be used as a risk stratification tool when combined 
with other risk markers in different patient populations.  
MARKERS OF ABNORMAL REPOLARIZATION OR 
ELECTRICAL INSTABILITY 
T Wave Alternans 
  Electrical alternans and, hence, action potential alternans 
result from changes in cardiac repolarization that occurs on a 
beat-to-beat basis. TWA testing involves measuring 
variations in the T wave morphology on an every-other-beat 
basis. Typically, this variation is on the order of a few 
microvolts and requires specialized signal processing 
methods. Two types of TWA testing are available: spectral 
analysis and modified moving average. Experimental and 
clinical studies have shown that abnormal TWA is associated 
with an increased risk of ventricular arrhythmias [26-28]. 
Most studies have found that the prognosis of patients with 
indeterminate TWA is similar to that of patients with 
abnormal or positive tests, so these patient groups are often 
combined.  
  A meta-analysis of 19 prospective studies of TWA 
between 1990 and 2004, including 2,608 subjects with heart 
failure, ischemic and non-ischemic cardiomyopathies, post-
MI, athletes, and healthy subjects reported an overall 19.3 % 
PPV of TWA for arrhythmic events, and a 97.2% NPV. 
Subjects with indeterminate TWA were excluded. There was 
no difference in predictive value between ischemic and 
nonischemic heart failure subgroups [29].  
  Results from early clinical trials using TWA as a risk 
stratification marker suggested that TWA has a similar 
prognostive value in ischemic and nonischemic cardio-
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(LVEF, EPS and NSVT), and identifies different populations 
at risk of arrhythmic events compared to those identified 
with LVEF, NSVT and EPS [30-33].  
 Bloomfield  et al. evaluated the predictive value of TWA 
in a multicenter prospective trial of 549 patients with LVEF 
 40% (mean LVEF=25%) and no previous history of 
sustained ventricular arrhythmias. The primary end point 
was all-cause mortality or non-fatal sustained ventricular 
arrhythmias. During a mean follow-up of 20 ± 6 months, 51 
endpoints occurred. The two-year event rate was 15.0% in 
the patients with a non-negative TWA and 2.5% in those 
with a negative TWA (hazard ratio (HR) = 6.5, p < 0.001). 
Interestingly, patients with a negative TWA and LVEF  
30% had a lower two-year event rate (3.5%) than patients 
with a non-negative TWA test and an LVEF between 31% 
and 40% (11.8%), suggesting that a negative TWA can help 
to assess the predictive value of a markedly depressed LVEF 
and could improve assessment of the potential benefit of 
prophylactic ICD therapy [34].  
  In the ALPHA study, 446 patients with nonischemic 
cardiomyopathy and LVEF 40% were followed for 18 to 24 
months. The primary endpoint was a combination of cardiac 
death and life-threatening arrhythmias. Primary endpoint 
rates in patients with abnormal and normal TWA tests were 
9.9% (n=292) and 2.5% (n=154), respectively. Although the 
NPV of a negative TWA test at 12 and 18 months exceeded 
97%, the PPV were relatively low (6.5% and 9.0% for the 
primary end point at 12 and 18 months) slightly increasing to 
7.9% and 10.9% at 12 and 18 months, respectively, among 
patients with LVEF 35%. The authors concluded that 
patients with nonischemic cardiomyopathy, LVEF 40%, 
and negative TWA have a very good prognosis and are likely 
to benefit little from ICD therapy [35]. However, 
interpretation of these results and their usefulness in clinical 
practice is limited by the low incidence of primary endpoint 
events in both groups. It also brings into question of the 
clinical value of a test with an excellent NPV, but a low 
PPV.  
  The preliminary results of the prospective clinical trial 
Alternans Before Cardioverter Defibrillator (ABCD) in 566 
patients with coronary artery disease, an LVEF <40%, and a 
history of nonsustained VT but no sustained ventricular 
arrhythmias who underwent both TWA and EPS were 
presented at the 2006 AHA Annual Scientific Sessions 
(Heartwire/The Heart.org). The protocol required those with 
a positive result on either test to be implanted with an ICD. 
If both tests were negative, an ICD was recommended but 
the decision was left to the clinician. The mean LVEF was 
28%. Preliminary data showed that no arrhythmic events 
were observed in 501 patients. The remaining 65 
experienced VT/VF, SCD, or antitachycardia pacing for VT 
termination; the event rate was 7.5% at one year and 14% at 
two years. The PPV of both tests was about 10% or less, and 
their NPV were nearly the same, about 96%. The PPV of 
EPS remained high over two years of follow-up, but the 
predictive value of TWA fell off after about 12 to 15 months, 
suggesting a potential need for periodic TWA for risk 
stratification [36].  
 Chow  et al. also evaluated the predictive value of TWA 
in a multicenter prospective trial of 768 patients with 
ischemic cardiomyopathy, LVEF 35% and no prior history 
of ventricular arrhythmia. The primary endpoint for the 
study was all-cause mortality and the secondary endpoint 
was a combination of cause-specific mortality and 
appropriate ICD shocks. Mean follow-up was 18±10 months. 
A non-negative TWA was associated with a significantly 
higher risk for all-cause (HR=2.24, p=0.002) and arrhythmic 
mortality (HR=2.29, p=0.049). In patients with ICDs, a non-
negative TWA showed a trend toward higher risk for 
appropriate ICD shocks (HR=3.79, p=0.07). When the 
analysis was limited only to those patients who tested TWA 
positive or negative, a positive TWA was associated with 
higher all-cause mortality (HR=2.08, p=0.01) and a trend 
toward higher arrhythmic mortality (HR=2.03, p=0.13) [37].  
  After multivariable adjustment, among the 392 (51%) 
patients who received ICDs in this multicenter trial, ICDs 
were associated with lower all-cause mortality in non-
negative TWA patients (HR=0.45, p=0.003) but not in the 
negative TWA patients (HR=0.85, p=0.73), with the 
mortality benefit in non-negative TWA patients largely due 
to reduction of arrhythmic mortality (p=0.004). The NNT 
with an ICD for two years to save one life was 9 among non-
negative TWA patients and 76 among negative TWA 
patients [38] (Fig. 2). Moreover, the observed mortality in 
this trial was 8.26% (n=254) versus 15.17% (n=514) in the 
negative TWA and non-negative TWA groups, respectively. 
In our opinion, the mortality in both groups is clinically 
significant and, therefore, it cannot be concluded that there is 
no significant benefit from ICD therapy in the negative 
TWA group, since data from seven primary prevention ICD 
trials showed an average 28% RRR and 3% absolute risk 
reduction of death in ICD treated patients as compared to 
medical therapy.  
  Recently, the MASTER I trial shed some light on this 
clinical dilemma. In this study, 654 patients with a MADIT 
II indication for ICD implantation were prospectively follo-
wed for a minimum of two years. Preliminary data analysis 
from 575 patients was reported at the 2007 AHA Annual 
Scientific Sessions (Heartwire/The Heart.org). The primary 
end point of life-threatening ventricular tachyarrhythmic 
events (as assessed by ICD shocks) was not significantly 
different between patients with negative and non-negative 
TWA (10.3% vs. 13.3%, p=0.37). Mortality results showed 
that all-cause deaths were increased in the patients with non-
negative tests, but this appeared to be accounted for mainly 
by an increase in noncardiac deaths. The investigators 
concluded that TWA testing should not be used to withhold 
ICDs in MADIT II-indicated patients [39].  
  Similarly, TWA failed to predict SCD, sustained VT/VF, 
or appropriate ICD therapy (HR 1.28, p=0.46) among 490 
patients with class II/III NYHA enrolled in a substudy from 
the Sudden Cardiac Death in Heart Failure (SCD-HeFT) trial 
[40]. Therefore, we can not conclusively say that patients 
with LVEF 30% do not benefit from prophylactic ICD 
therapy, regardless of their TWA test results. However, we 
can say that patients with negative TWA and LVEF  30% 
seem to have less benefit. This observation could be 
clinically relevant when patients are informed about the risks 
and benefits of prophylactic ICD therapy, since patients 
should be involved in the decision making about their care.  
  The role of TWA in the risk stratification of patients with 
LVEF >35% has not been well studied.  60  Current Cardiology Reviews, 2009, Vol. 5, No. 1  Lopera and Curtis 
 Inama  et al. reported a significant correlation of induci-
bility of VT during EPS and positive or indeterminate TWA 
among 85 athletes with normal LVEF and complex 
ventricular arrhythmias [41].  
  The predictive value of TWA for overall mortality in
 a 
general population was tested in the Finnish Cardiovascular 
Study in 1037 consecutive patients referred for an exercise
 
test. During a follow-up
 of 44±7 months, 59 patients died. 
Adjusted multivariate analysis demonstrated a statistically 
significant relative risk of SCD (RR= 7.4, p<0.001; PPV=8% 
and NPV=98.6%) and all-cause mortality (RR=3.3, p=0.001; 
PPV=14.9% and NPV=95.2%) among subjects with TWA 
>65  V. LVEF was reported in 529 patients (65±15%). 
There were 67 patients (12.7%)
  with an EF <50%, and 8 
patients (1.5%) presented with
 an EF <30%. Although SCD 
and mortality risk were not adjusted to LVEF, this study 
does suggest that TWA could add prognostive value to 
routine exercise stress testing in the general population [42].  
  However, the predictive value of TWA varies depending 
on the pretest probability for arrhythmic events of the 
population being studied. For example, the PPV varied 
depending on the population of patients studied; it was 
25.5% at 18 months in heart failure patients and 6% in post-
MI patients (p<0.0001) (Fig. 3). Nonetheless, the NPV 
remained adequate in both groups, 96.3% versus 99.4%, 
respectively [29].  
  Future risk stratification studies will likely use a 
combination of risk markers, perhaps even in combination 
with genetic profiling, for SCD risk stratification in larger 
population groups that include much higher numbers of 
potential SCD victims.  
Electrophysiology Studies 
  The predictive value of inducing sustained VT/VF during 
EPS (positive EPS) was tested in two large prospective 
multicenter trials (MADIT, MUSTT). These trials 
demonstrated that a positive EPS in patients with prior MI, 
LVEF  40% and NSVT identifies populations with a 
substantial benefit from prophylactic ICD therapy, with a 
56% and 76% RRR of overall mortality and cardiac arrest 
and arrhythmic death, respectively [43-45].  
  More specifically, the prognostic value of positive EPS in 
353 MUSTT patients who were randomized not to receive 
antiarrhythmic therapy was compared to that of negative 
EPS among 1397 patients who were followed in the MUSTT 
registry. The primary end point
 was cardiac arrest or death 
from arrhythmia. Patients were followed for a median of 39 
months. The two-year and five-year rates
 of cardiac arrest or 
death due to arrhythmia were 12 and 24
  %, respectively, 
among the patients in the registry, as
 compared with 18 and 
32% among the patients with inducible
  tachyarrhythmias 
who were assigned to no antiarrhythmic therapy
  (adjusted 
P<0.001). Overall mortality after five years was
 48% among 
the patients with inducible tachyarrhythmias,
  as compared 
with 44% among the patients in the registry
  (adjusted 
P=0.005) [46]. However, even patients without inducible 
tachyarrhythmias had
  a relatively high risk of death, 
indicating that patients with negative EPS still had high 
mortality rates and could potentially benefit from 
prophylactic ICD therapy.  
 
Fig. (2). The number needed to treat to save a life varies depending on the risk stratification tools used: 4 when MADIT I/MUSTT risk 
stratification was used; 18 in MADIT II. However, if TWA was used in MADIT II-like patients, the number needed to treat to save a life 
changes to 9 if TWA non-negative or 76 if TWA negative. TWA=T wave alternans.  Risk Stratification for Sudden Cardiac Death  Current Cardiology Reviews, 2009, Vol. 5, No. 1  61 
  The presence of inducible sustained
  ventricular 
tachycardia proved to be a relatively specific predictor
  of 
death from arrhythmia in this group of patients. The 
proportion
  of deaths classified as due to arrhythmia was 
greater among
 the patients with inducible tachyarrhythmias 
who were randomly
  assigned to no antiarrhythmic therapy 
than among the patients
 in the registry, in whom sustained 
tachyarrhythmias could not
  be induced. In the MUSTT 
registry, the two year negative predictive value of EPS for 
cardiac arrest or death due to arrhythmia
 was 88%. However, 
the negative predictive value of EPS may diminish with time 
as coronary artery disease and LV dysfunction worsen [46].  
  As mentioned earlier, data analysis from 674 patients 
enrolled in the MUSTT study who did not receive 
antiarrhythmic or ICD therapy revealed that the prognostic 
value of LVEF and inducible sustained ventricular 
tachycardia is influenced by other variables, such as 
functional class, history of heart failure, NSVT, age, left 
ventricular conduction abnormalities, and atrial fibrillation 
[19]. These findings suggest that risk stratification 
algorithms should include several markers of risk, especially 
in patients with LVEF >35%.  
  In the MADIT II study, 593 (82%) of 720 patients 
randomized to the ICD arm also underwent EPS. Inducible 
patients had a greater likelihood of experiencing ICD therapy 
for spontaneous VT than non-inducible patients (p=0.023). 
However, ICD therapy for spontaneous VF was less frequent 
in inducible patients. Therefore, the two-year event rate for 
combined VT/VF was 29.4% for inducible patients and 
25.5% for noninducible patients. (p = 0.280). In other words, 
a positive EPS is a good predictor of VT, but not a good 
predictor of VF [47].  
  These data reinforce the concept that EPS provides 
important but limited prognostic information. Today, EPS 
still has a role in the risk stratification of asymptomatic 
patients with NSVT, coronary artery disease and LVEF 
between 30-40% in the absence of heart failure symptoms. It 
also has a significant role in the risk stratification of 
symptomatic patients (syncope) and LVEF >40%.  
Signal Averaged Electrocardiography 
  The SAECG is a highly amplified and signal-processed
 
ECG that can detect microvolt-level
 electrical potentials in 
the terminal QRS complex, known as
 late potentials. These 
arise from scarred myocardium, which
  can be a source of 
reentrant malignant ventricular arrhythmias. An abnormal 
SAECG (filtered QRS
 duration >114 ms) has been correlated 
with inducibility
 of VT [48].  
  A meta-analysis of 20 clinical studies in post-MI patients 
(n=9883) showed that an abnormal SAECG had a positive 
predictive value ranging from 6 to 35% in forcasting major 
arrhythmic events [49].  
  The predictive value of SAECG was evaluated in 1268 
patients (66%) out of 1925 patients enrolled in the MUSTT 
trial who had a baseline SAECG. In subjects with an 
abnormal SAECG, the 5-year rates of the
 primary end point 
of arrhythmic death or cardiac arrest (28% vs. 17%, 
P=0.0001), cardiac death
 (37% vs. 25%, P=0.0001), and total 
mortality (43% vs. 35%, P=0.0001) were significantly higher 
[48].  
  In the CABG Patch Trial, 900 patients scheduled for 
elective coronary bypass
 surgery with an LVEF  35% and an
 
abnormal SAECG were randomly assigned to therapy with 
an ICD (446 patients) or to the control
 group (454 patients). 
The primary endpoint of the study was
  overall mortality. 
During an average follow-up of 32±16
 months, there were 
101 deaths in the defibrillator group and 95 in the control 
 
Fig. (3). The positive predictive value of T wave alternans varies depending on the pretest probability for arrhythmic events of the population 
being studied. For example, the positive predictive value can vary from 25% in congestive heart failure patients to 6% in post-myocardial 
infarction patients. (Reprinted with permission Elsevier Limited).  62  Current Cardiology Reviews, 2009, Vol. 5, No. 1  Lopera and Curtis 
group (hazard ratio =1.07; P=0.64). Revascularization may 
have altered
  the immediate prognosis irrespective of the 
SAECG and EF. On
 the other hand, in many patients, EF 
may have improved after
 revascularization, or the substrate 
for arrhythmogenesis could
 have been substantially altered. 
Further
 analysis of the CABG Patch study showed that ICD 
use reduced
  arrhythmic death by 45%, although total 
mortality was not reduced
  because of an increase in non-
arrhythmic deaths [50].  
 Observations
  from these studies are not necessarily 
contradictory, since they compared different patient 
populations and different definitions of an abnormal SAECG 
were used (filtered QRS
 duration >114 ms in MUSTT vs. 
filtered QRS
 duration >114 ms; root-mean-square voltage in 
the terminal
  40 msec of the QRS complex <20 V; or 
duration of
 the terminal filtered QRS complex at <40 V >38
 
ms in the CABG Patch Trial). Hence, the SAECG might still 
have a role in risk stratification
 for arrhythmic death.  
MARKERS OF ABNORMAL AUTONOMIC 
BALANCE 
  There is a close relation between the autonomic nervous 
system and arrhythmogenesis. Heart rate variability (HRV) 
and baroreflex sensitivity (BRS) have become important 
methods for assessing
  cardiovascular autonomic regulation 
and have
  been extensively studied for their value
  as 
predictors of total mortality, SCD, and the occurrence of
 
ventricular tachyarrhythmias. Initial animal experiments in 
dogs with healed myocardial infarction by Schwartz et al. 
demonstrated that the presence of reduced BRS is associated 
with a greater susceptibility to ventricular fibrillation during 
subsequent ischemic episodes [20,51-53].  
  A meta-analysis of 11 clinical studies in post-MI patients 
(n=5719) showed that an abnormal HRV had a PPV ranging 
from 9 to 54% in predicting major arrhythmic events (49). 
On the other hand, in a single center, prospective study of 
700 post MI patients on adequate beta blocker therapy, 
Huikuri et al. reported that autonomic markers (HVR, BRS) 
did not predict SCD [23].  
  In the ATRAMI trial, the prognostic value of HRV and 
BRS were assessed prospectively in 1284 post-MI patients. 
Low HRV (Standard deviation of R-R interval, SDNN <70 
ms) or BRS (<3.0 ms per mm Hg) values carried a 
significant mortality risk (HR=3.2 and 2.8, respectively). 
The association of low SDNN and BRS further increased 
risk; the 2-year mortality was 17% when both were below 
the cut-offs and 2% (p<0.0001) when both were well 
preserved (SDNN >105 ms, BRS >6.1 ms per mm Hg). The 
association of low SDNN or BRS with LVEF <35% carried 
a relative risk of 6.7 or 8.7 (4.3-17.6), respectively, 
compared with patients with LVEF 35% and less 
compromised SDNN (>70 ms) and BRS (>3 ms per mm 
Hg). These results suggest that assessment of autonomic 
balance provides important prognostic information in post 
MI patients [54].  
  In the DINAMIT trial, 674 patients with a recent MI (6-
40 days), LVEF  35% and low HRV (SDNN <70ms) or a 
mean RR interval  750
 ms were randomly assigned
 to the 
ICD group (n=332) or to the control group (n=342). The 
primary
  outcome was mortality from any cause. During a 
mean follow-up period of 30±13
  months, there was no 
difference in overall mortality between
  the two treatment 
groups. A significant decrease in arrhythmic death was 
observed, 12 (ICD group) versus 29 (control group) 
(p=0.009). However, this effect
 was offset by a significant 
increase in non-arrhythmic death, 50 (ICD group) vs. 29 
(control group), p=0.02. The reason for this increase in
 non-
arrhythmic mortality in the ICD group is not clear, since it 
has not been observed in other primary prevention ICD 
trials. The predictive value of abnormal HRV (SDNN <60 
ms) was not clinically significant [55].  
CONCLUSION 
  We have made significant progress in the risk 
stratification of SCD. The combination of various risk 
markers in primary prevention ICD trials (LVEF, NSVT, 
EPS) have allowed the identification of patients at risk who 
could benefit from prophylactic ICD therapy. At the present 
time, LVEF remains the single most important marker for 
risk stratification. According to current guidelines, most 
patients with LVEF <35% could benefit from prophylactic 
ICD implantation, particularly in the setting of symptomatic 
heart failure [56]. Other risk stratifiers, such as T wave 
alternans, give additional prognostic information. However, 
because there is no method with a negative predictive value 
of 100%, most physicians have been reluctant to base 
decisions on ICD implantation solely on the basis of such 
test results. On the other hand, risk markers can been useful 
in borderline cases or when patients or physicians are 
reluctant to pursue ICD implantation without further data.  
  In addition, current risk stratification strategies fail to 
identify patients at risk of SCD in larger population groups 
encompassing a greater number of potential SCD victims 
[11]. In other words, current guidelines for prophylactic ICD 
therapy only identify a minority of the SCD victims.  
  It is clear that patients with normal or mildly depressed 
LVEFs (>35%) have a better prognosis and lower risk of 
serious cardiac arrhythmias. We have shown from small and 
large, single center and multicenter clinical trials that 
markers of abnormal substrate or structural heart disease 
(LVEF, NSVT, frequent ventricular ectopy, QRS duration), 
markers of abnormal repolarization or electrical instability 
(EPS, TWA, SAECG) and markers of abnormal autonomic 
balance (HRV and BRS) provide important prognostic 
information in a wide range of clinical situations. The 
challenge that lays ahead is the implementation of risk 
stratification strategies that can reliably predict risk in 
patients with LVEF >35%. We have also shown that in this 
group of patients, risk stratification strategies will require the 
use of a combination of several risk markers, but risk 
stratification strategies will need to be tested in large 
prospective multicenter clinical trials before they can be 
incorporated into daily clinical practice.  
ABBREVIATIONS 
ARR  =  Absolute risk reduction 
BRS =  Baroreceptor  sensitivity 
EPS =  Electrophysiology  study 
HR =  Hazard  ratio Risk Stratification for Sudden Cardiac Death  Current Cardiology Reviews, 2009, Vol. 5, No. 1  63 
HRV  =  Heart rate variability 
ICD =  Implantable  cardioverter  defibrillator 
LVEF  =  Left ventricular ejection fraction 
MI =  Myocardial  infarction 
NNT  =  Number needed to treat 
NPV  =  Negative predictive value 
NSVT = Non-sustained  ventricular  tachycardia 
PPV  =  Positive predictive value 
RRR  =  Relative risk reduction  
SAECG  =  Signal averaged electrocardiography 
SCD  =  Sudden cardiac death 
SDNN  =  Standard deviation of R-R interval 
TWA =  T  wave  alternans 
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